Patents by Inventor Florian Sohler

Florian Sohler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies binding ALK-1 and BMPR-2
    Publication number: 20220185901
    Abstract: The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g., of pulmonary hypertension.
    Type: Application
    Filed: February 25, 2022
    Publication date: June 16, 2022
    Inventors: Ernst WEBER, Joerg MEDING, Florian SOHLER, Julian Marius GLUECK
  • Bispecific antibodies binding ALK-1 and BMPR-2
    Patent number: 11292846
    Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: April 5, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck
  • Bispecific antibodies binding ALK-1 and BMPR-2
    Publication number: 20200332013
    Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.
    Type: Application
    Filed: October 25, 2018
    Publication date: October 22, 2020
    Inventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck